간호사와 의사의 항암화학요법의 이독성에 대한 인식과 관리실태
Nurses’ and Medical Doctors’ Perception and Management Status on Ototoxicity Related to Chemotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study was to investigate the perception of ototoxicity related to chemotherapy (cisplatin) and management status among nurses and doctors. Methods: The participating subjects were 247 nurses working in the oncology ward and the anti-cancer injection room and 40 internal medicine doctors in C University Hospital of D City. The data were collected from October to November 2019, using a self-report structured questionnaire and analyzed by the SPSS/WIN 24.0 program. Results: As a result of this study, 51.4% of nurses answered that they had knowledge of ototoxicity, 33.5% provided prior information on ototoxicity, and 4.5% provided information on the hearing test before cisplatin administration. The group with knowledge of cisplatin-related ototoxicity provided more information on both ototoxicity (χ2=105.02, p<.001) and hearing test (χ2=5.27, p=.022) than the group without knowledge of ototoxicity. The provision of education, including the contents of ototoxicity, improved the nurses’ knowledge about cisplatin-related ototoxicity, and it was found that more information about hearing loss was provided. Conclusion: It was confirmed that education on the symptoms of cisplatin-related ototoxicity was required and no ototoxicity management system was in place. Therefore, it is necessary to develop an ototoxicity management program at the hospital level, which will have an effect on improving nursing practice for cancer patients.
Abstract
Purpose: The purpose of this study was to investigate the perception of ototoxicity related to chemotherapy (cisplatin) and management status among nurses and doctors. Methods: The participating subjects were 247 nurses working in the oncology ward and the anti-cancer injection room and 40 internal medicine doctors in C University Hospital of D City. The data were collected from October to November 2019, using a self-report structured questionnaire and analyzed by the SPSS/WIN 24.0 program. Results: As a result of this study, 51.4% of nurses answered that they had knowledge of ototoxicity, 33.5% provided prior information on ototoxicity, and 4.5% provided information on the hearing test before cisplatin administration. The group with knowledge of cisplatin-related ototoxicity provided more information on both ototoxicity (χ2=105.02, p<.001) and hearing test (χ2=5.27, p=.022) than the group without knowledge of ototoxicity. The provision of education, including the contents of ototoxicity, improved the nurses’ knowledge about cisplatin-related ototoxicity, and it was found that more information about hearing loss was provided. Conclusion: It was confirmed that education on the symptoms of cisplatin-related ototoxicity was required and no ototoxicity management system was in place. Therefore, it is necessary to develop an ototoxicity management program at the hospital level, which will have an effect on improving nursing practice for cancer patients.
참고문헌 (19)
- "International agency for research on cancer, the global cancer observatory Web site"[URL]
- A. Jemal, "Cancer Statistics, 2010", CA: A Cancer Journal for Clinicians, 60(5), pp.277~300 (2010), Wiley[DOI]
- "Chemotherapy to treat cancer Web site"[URL]
- Arora R, "Cisplatin-based chemotherapy : add high-frequency audiometry in the regimen", Indian J Cancer, 46, pp.311~317 (2009)
- Yorgason JG, "Understanding drug ototoxicity : molecular insights for prevention and clinical management", Expert Opin Drug Saf, 5, pp.383~399 (2006)[DOI]
- Schellack Natalie, "An overview of pharmacotherapy-induced ototoxicity", South African Family Practice, 55(4), pp.357~365 (2013), AOSIS[DOI]
- Barr-Hamilton RM, "Ototoxicity of cisplatinum and its relationship to eye colour", J Laryngol Otol, 105, pp.7~11 (1991)
- Paken J, "Cisplatin-associated ototoxicity : a review for the health professional", J Toxicol, 1809394, pp.1~13 (2016)[DOI]
- Herbst KG, "Hearing impairment and mental state in the elderly living at home", Br Med J, 281, pp.903~905 (1980)[DOI]
- N Sarala, "Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case series follow-up study", Journal of Cancer Research and Therapeutics, 14(5), pp.1099~1104 (2018), Medknow[DOI]
- Tange RA, "The importance of high tone audiometry in monitoring for ototoxicity", Arch Otorhinolaryngol, 242, pp.77~81 (1985)
- "Guideline for the audiologic management of individuals receiving cochleotoxic drug therapy"[URL]
- Maru D, "Current practice of ototoxicity management across the United Kingdom (UK)", Int J Audiol, 20, pp.1~13 (2018)[DOI]
- Anna Wium, "Ototoxicity management: An investigation into doctors’ knowledge and practices, and the roles of audiologists in a tertiary hospital", South African Journal of Communication Disorders, 63(1), pp.1~15 (2016), AOSIS[DOI]
- Greene JB, "Incidence of cisplatin induced ototoxicity in adults with head and neck cancer", Advances in Otolaryngology, 245613, pp.1~4 (2015)[DOI]
- Callie Berkowitz, "Head and Neck Cancer Survivors: Specific Needs and Their Implications for Survivorship Care Planning", Clinical Journal of Oncology Nursing, 22(5), pp.523~528 (2018), Oncology Nursing Society (ONS)[DOI]
- Simon J. Crabb, "COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss", European Journal of Cancer, 87, pp.75~83 (2017), Elsevier BV[DOI]
- Wendy Landier, "Ototoxicity and cancer therapy", Cancer, 122(11), pp.1647~1658 (2016), Wiley[DOI]
- Garinis AC, "Ototoxicity monitoring through the eyes of the treating physician : perspectives from pulmonology and medical oncology", Int J Audiol, 57, pp.19~24 (2018)[DOI]